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Abstract
© 2016 The Author(s)Myalgic encephalomyelitis (ME) is a complex, heterogeneous illness of
unknown etiology. The search for biomarkers that can delineate cases from controls is one of
the most active areas of ME research; however, little progress has been made in achieving this
goal. In contrast to identifying biomarkers that are directly involved in the pathological process,
an immunosignature identifies antibodies raised to proteins expressed during, and potentially
involved in, the pathological process. Although these proteins might be unknown, it is possible
to detect antibodies that react to these proteins using random peptide arrays. In the present
study, we probe a custom 125,000 random 12-mer peptide microarray with sera from 21 ME
cases and 21 controls from the USA and Europe and used these data to develop a diagnostic
signature.  We  further  used  these  peptide  sequences  to  potentially  uncover  the  naturally
occurring candidate antigens to which these antibodies may specifically react with in vivo. Our
analysis  revealed a subset of  25 peptides that  distinguished cases and controls  with high
specificity and sensitivity. Additionally, Basic Local Alignment Search Tool (BLAST) searches
suggest that these peptides primarily represent human self-antigens and endogenous retroviral
sequences and, to a minor extent, viral and bacterial pathogens.
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